Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Celldex Therapeutics (CLDX)

Celldex Therapeutics (CLDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 232,091
  • Shares Outstanding, K 22,555
  • Annual Sales, $ 3,570 K
  • Annual Income, $ -50,880 K
  • 60-Month Beta 3.46
  • Price/Sales 65.71
  • Price/Cash Flow N/A
  • Price/Book 2.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.77
  • Number of Estimates 1
  • High Estimate -0.77
  • Low Estimate -0.77
  • Prior Year -0.84
  • Growth Rate Est. (year over year) +8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.59 +14.44%
on 07/29/20
13.49 -18.64%
on 07/23/20
-1.45 (-11.71%)
since 07/02/20
3-Month
2.20 +398.86%
on 05/14/20
13.91 -21.10%
on 06/19/20
+8.72 (+385.62%)
since 05/01/20
52-Week
1.50 +631.67%
on 03/19/20
13.91 -21.10%
on 06/19/20
+8.84 (+412.85%)
since 08/02/19

Most Recent Stories

More News
Celldex to Report Second Quarter 2020 Financial Results and Host Corporate Update Call

Celldex Therapeutics, Inc. (Nasdaq:CLDX) will report second quarter 2020 financial results on Thursday, August 6, 2020 after the U.S. financial markets close. Celldex executives will host a conference...

CLDX : 10.83 (+5.25%)
Celldex Therapeutics, Inc. (CLDX) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Celldex Therapeutics, Inc. (CLDX).

CLDX : 10.83 (+5.25%)
The Global Breast Cancer Drugs Market is expected to grow from USD 15,188.90 Million in 2019 to USD 25,364.27 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 8.92%

, /PRNewswire/ --Read the full report: The Global Breast Cancer Drugs Market is expected to grow from in 2019 to by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 8.92%.Market Segmentation...

ABBV : 97.11 (+2.32%)
ALPMF : 15.8200 (-1.13%)
CELGZ : 0.47 (+2.15%)
CLDX : 10.83 (+5.25%)
MGNX : 26.69 (+5.08%)
MRK : 83.03 (+3.48%)
NVS : 84.14 (+2.43%)
Celldex Therapeutics Announces Closing of $150.0 Million Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Celldex Therapeutics, Inc. ("Celldex" or the "Company") (Nasdaq: CLDX), today announced the closing of its underwritten public offering of 15,384,614 shares (including 2,006,688 shares sold pursuant to...

CLDX : 10.83 (+5.25%)
Celldex Therapeutics Announces Pricing of $130.4 Million Public Offering of Common Stock

Celldex Therapeutics, Inc. ("Celldex" or the "Company") (Nasdaq: CLDX), today announced the pricing of its previously announced underwritten public offering. Celldex is offering 13,377,926 shares of its...

CLDX : 10.83 (+5.25%)
Celldex Therapeutics Announces Proposed Public Offering of Common Stock

Celldex Therapeutics, Inc. ("Celldex" or the "Company") (Nasdaq: CLDX), today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten...

CLDX : 10.83 (+5.25%)
Thinking about buying stock in Celldex Therapeutics, eMagin Corp, TOP Ships, Party City, or Alaska Air?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLDX, EMAN, TOPS, PRTY, and ALK.

ALK : 34.31 (-0.38%)
CLDX : 10.83 (+5.25%)
EMAN : 1.0600 (-2.75%)
PRTY : 1.7200 (+4.88%)
Implied Volatility Surging for Celldex Therapeutics (CLDX) Stock Options

Investors need to pay close attention to Celldex Therapeutics (CLDX) stock based on the movements in the options market lately.

CLDX : 10.83 (+5.25%)
Celldex's KIT Inhibitor CDX-0159 Demonstrates Profound, Sustained Dose-dependent Reductions in Plasma Tryptase--an Indicator of Mast Cell Burden--and a Favorable Safety Profile

--Data strongly support expanding development into mast cell driven diseases--

CLDX : 10.83 (+5.25%)
Is Celldex Therapeutics (CLDX) Stock Outpacing Its Medical Peers This Year?

Is (CLDX) Outperforming Other Medical Stocks This Year?

CLDX : 10.83 (+5.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CLDX with:

Business Summary

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal...

See More

Key Turning Points

2nd Resistance Point 11.06
1st Resistance Point 10.68
Last Price 10.83
1st Support Level 9.89
2nd Support Level 9.48

See More

52-Week High 13.91
Last Price 10.83
Fibonacci 61.8% 9.17
Fibonacci 50% 7.70
Fibonacci 38.2% 6.24
52-Week Low 1.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar